Table 2. Combination treatment assay.
| Therapeutic | Cell line | Cancer | Combination index |
|---|---|---|---|
| CDDP | A549 | Lung | 0.172 |
| Paclitaxel | LNCaP | Prostate | 0.219 |
| Doxorubicin | Hep3B | Liver | 0.252 |
| Everolimus | MKL-1 | NET | 0.354 |
| 5-FU | HCT-116 | Colon | 0.36 |
| Oxaliplatin | Lovo | Colon | 0.493 |
| Erlotonib | A549 | Lung | 0.509 |
| Sorafenib | Hep3B | Liver | 0.536 |
| Docetaxel | LNCaP | Prostate | 0.543 |
| 5-FU | Lovo | Colon | 0.597 |
| Gemcitabine | A549 | Lung | 0.647 |
| CDDP | HCT-116 | Colon | 0.687 |
| Erlotonib | BxPC3 | Pancreatic | 0.691 |
| Docetaxel | A549 | Lung | 0.724 |
| CDDP | N87 | Gastric | 0.757 |
| Sorafenib | A549 | Lung | 0.846 |
| Gemcitabine | PANC-1 | Pancreatic | 0.895 |
| Paclitaxel | A549 | Lung | 1.01 |
| Gemcitabine | Capan-1 | Pancreatic | 1.02 |
| 5-FU | ZR-75-1 | Breast | 1.05 |
| Docetaxel | N87 | Gastric | 1.05 |
| Paclitaxel | N87 | Gastric | 1.1 |
Combination indices were calculated using the Chou-Talay method. Cells were exposed concomitantly to both drugs for 72 hours and cytotoxicity determined using the MTT assay. The Combination Index (CI) values were calculated using the Compusyn® program. CI values of 0.90–1.10 indicate additive effects. CI values of < 0.90 indicate synergy (the smaller the value, the greater the degree of synergy).